How Fluorine-18-labeled Fluorodeoxyglucose PET Changed Clinical Practice in Central Nervous System Disorders - 06/07/26

Doi : 10.1016/j.cpet.2026.06.002

Eric Guedj, MD, PhD ^a,^⁎ , Andrew B. Newberg, MD ^b,^c, Abass Alavi, MD ^d

^a Aix Marseille University, APHM, CNRS, Centrale Marseille, Institut Fresnel, Timone Hospital, CERIMED, Nuclear Medicine Department, Marseille, France

^b Department of Integrative Medicine and Nutritional Sciences

^c Department of Radiology, Research at the Marcus Institute of Integrative Health, Thomas Jefferson University, Philadelphia, PA, USA

^d Division of Nuclear Medicine, Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA

^∗ Corresponding author. Laboratoire de Médecine Nucléaire, Hôpital de la Timone, 264 rue Saint Pierre, 13005 Marseille, France. Laboratoire de Médecine Nucléaire Hôpital de la Timone 264 rue Saint Pierre Marseille 13005 France

Sous presse. Épreuves corrigées par l'auteur. Disponible en ligne depuis le Monday 06 July 2026
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder

Résumé

Over 5 decades, fluorine-18-labeled fluorodeoxyglucose ([18F]FDG) PET has transformed clinical practice in central nervous system (CNS) disorders by enabling in vivo assessment of brain metabolism as a surrogate of functional integrity. Beyond structural imaging, it provides reproducible, pattern-based biomarkers that improve diagnostic accuracy in dementia, epilepsy, and selected neuroinflammatory conditions. In the evolving biomarker landscape, [18F]FDG PET remains uniquely positioned to capture downstream network dysfunction and phenotypic expression of disease. Supported by standardized methodologies and expanding analytical approaches, it continues to play a central role in differential diagnosis, prognostic assessment, and integrated precision neurology.

Le texte complet de cet article est disponible en PDF.

Keywords : [18F]FDG PET, Brain metabolism, Neuroimaging, Biomarkers, Central nervous system, Neurodegenerative disorders, Epilepsy, Autoimmune encephalitis